JonesTrading analyst Soumit Roy maintained a Buy rating on Cassava Sciences (SAVA – Research Report) today and set a price target of $75.00. The company’s shares opened today at $20.67.
Roy covers the Healthcare sector, focusing on stocks such as Cassava Sciences, Anavex Life Sciences, and Mirati Therapeutics. According to TipRanks, Roy has an average return of -5.6% and a 26.13% success rate on recommended stocks.
Currently, the analyst consensus on Cassava Sciences is a Moderate Buy with an average price target of $99.50.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $51.59 and a one-year low of $16.55. Currently, Cassava Sciences has an average volume of 910.6K.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SAVA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.
Read More on SAVA:
- Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease
- Cassava Sciences announces science publication on activity of simufilam
- Largest borrow rate increases among liquid names
- ClinicalTrials post shows Cassava RETHINK-ALZ study done recruiting
- Cassava Sciences Invited to Present in Four Upcoming Investor Conferences
